Kevin McBride joined the AmorChem team as Director, Project Management in January 2013. Dr. McBride is a multidisciplinary scientist who has more than twenty years of biomedical research and project management experience, comprising both fundamental academic research as well as applied drug discovery efforts in the biotech sector. He obtained his M.Sc. (Analytical Chemistry) degree from Queen's University (Belfast) and subsequently moved to England where he performed his doctoral research (biochemistry) at the School of Pharmacy, University of London. He became a Senior Investigator at the IRCM (Cardiac Growth & Differentiation lab) in Montreal following his postdoctoral work, and in 2001 was invited to join and lead a molecular biology team for Compatigene Inc., a biotech company working on cancer immunotherapeutics. He made significant contributions to the rapid identification of a mouse/human gene encoding an immunodominant epitope on the surface of cancer. After Compatigene, Kevin continued further in the biotech field by joining Chronogen Inc. (2003) where he led a team that discovered and developed an inhibitor of an anti-aging target in animals that eventually achieved proof-of-concept as a candidate Alzheimer's disease therapeutic. He remained a consultant to EnVivo Pharma Inc. after its acquisition of the Chronogen target.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Creative Destruction Lab (CDL) | Associate | — | — | Detail |